Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
Standard
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. / Winkler, K; Beron, G; Kotz, R; Salzer-Kuntschik, M; Beck, J; Beck, W; Brandeis, W; Ebell, W; Erttmann, Rudolf; Göbel, U.
in: J CLIN ONCOL, Jahrgang 2, Nr. 6, 6, 1984, S. 617-624.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
AU - Winkler, K
AU - Beron, G
AU - Kotz, R
AU - Salzer-Kuntschik, M
AU - Beck, J
AU - Beck, W
AU - Brandeis, W
AU - Ebell, W
AU - Erttmann, Rudolf
AU - Göbel, U
PY - 1984
Y1 - 1984
N2 - From December 1979 to August 1982 158 patients were registered for an adjuvant chemotherapy (CT) study COSS -80. To compare the effect of cisplatin (CPL) to that of the drug combination bleomycin, cyclophosphamide, and dactinomycin (BCD), patients were randomized to receive either drug(s) within a course of sequential multidrug CT including doxorubicin and high-dose methotrexate (HDMTX). Definite surgery was done 10-18 weeks after the start of CT. Patients were randomized a second time to receive or not to receive fibroblast interferon in addition to CT beginning at week 16. At a median observation time of 19.5 months (range, 4-34 months), 116 (73%) of 158 patients were continuously disease-free (CDF). After exclusion of 42 patients because of some deviation in history and/or management, 86 (74%) of 116 patients actually were CDF with a 30-month calculated CDF-rate of 68%. There was no difference in CDF rates in the patients receiving BCD versus CPL or receiving interferon versus no interferon. Whereas, in comparison to the previous study COSS -77, the over-all increase in CDF rate does not reach statistical significance, it does, however, for the younger (less than or equal to 12 years) and for male patients, which is assumed to be the effect of increasing the methotrexate dose from 6 to 12 g/m2 in the COSS -80 study.
AB - From December 1979 to August 1982 158 patients were registered for an adjuvant chemotherapy (CT) study COSS -80. To compare the effect of cisplatin (CPL) to that of the drug combination bleomycin, cyclophosphamide, and dactinomycin (BCD), patients were randomized to receive either drug(s) within a course of sequential multidrug CT including doxorubicin and high-dose methotrexate (HDMTX). Definite surgery was done 10-18 weeks after the start of CT. Patients were randomized a second time to receive or not to receive fibroblast interferon in addition to CT beginning at week 16. At a median observation time of 19.5 months (range, 4-34 months), 116 (73%) of 158 patients were continuously disease-free (CDF). After exclusion of 42 patients because of some deviation in history and/or management, 86 (74%) of 116 patients actually were CDF with a 30-month calculated CDF-rate of 68%. There was no difference in CDF rates in the patients receiving BCD versus CPL or receiving interferon versus no interferon. Whereas, in comparison to the previous study COSS -77, the over-all increase in CDF rate does not reach statistical significance, it does, however, for the younger (less than or equal to 12 years) and for male patients, which is assumed to be the effect of increasing the methotrexate dose from 6 to 12 g/m2 in the COSS -80 study.
M3 - SCORING: Zeitschriftenaufsatz
VL - 2
SP - 617
EP - 624
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 6
M1 - 6
ER -
